Bevacizumab in Treating Young Patients With Refractory Solid Tumors

Inclusion Criteria:

* Histologically confirmed solid tumor at original diagnosis
* Measurable or evaluable\* disease
* No known curative therapy exists
* No lymphomas or primary CNS tumors
* No history or clinical evidence of CNS metastasis by head CT scan
* Performance status - Karnofsky 50-100% (patients \> 10 years of age)
* Performance status - Lansky 50-100% (patients ≤ 10 years of age)
* At least 8 weeks
* Patients without bone marrow involvement:

  * Absolute neutrophil count ≥ 1,000/mm\^3
  * Platelet count ≥ 100,000/mm\^3 (transfusion independent)
  * Hemoglobin ≥ 8.0 g/dL (RBC transfusion allowed)
* Patients with bone marrow metastases:

  * Platelet count ≥ 75,000/mm\^3 (transfusion independent)
  * Granulocytopenia, anemia, and/or mild thrombocytopenia allowed
* No known bleeding diathesis or coagulopathy
* No known thrombophilic condition (e.g., protein S, protein C, or antithrombin III deficiency, Factor V Leiden, Factor II G20210A mutation, homocystinemia, or antiphospholipid antibody syndrome)
* PT or PTT ≤ 1.2 times upper limit of normal (ULN)
* ALT ≤ 5 times ULN
* Bilirubin ≤ 1.5 times ULN
* Albumin ≥ 2 g/dL
* Creatinine clearance or radioisotope glomerular filtrationrate ≥ 70 mL/min
* Creatinine based on age as follows:

  * Creatinine ≤ 0.8 mg/dL (patients ≤ 5 years of age)
  * Creatinine ≤ 1.0 mg/dL (patients 6 to 10 years of age)
  * Creatinine ≤ 1.2 mg/dL (patients 11 to 15 years of age)
  * Creatinine ≤ 1.5 mg/dL (patients \> 15 years of age)
* No proteinuria
* 24-hour urine protein ≤ 500 mg
* No history of stroke
* No deep venous or arterial thrombosis within the past 3 months
* No uncontrolled hypertension

  * Hypertension must be well-controlled with stable doses of medication for at least 2 weeks
* No history of myocardial infarction
* No severe or unstable angina
* No transient ischemic attack within the past 6 months
* No cerebrovascular accident within the past 6 months
* No other arterial thromboembolic event within the past 6 months
* No clinically significant or severe peripheral vascular disease
* No pulmonary embolism within the past 3 months
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception during and for at least 3 months after study participation
* No chronic non-healing wound, ulcer, or bone fracture
* No significant traumatic injury within the past 28 days
* No uncontrolled seizures
* No uncontrolled infection
* No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
* Recovered from prior immunotherapy
* More than 1 week since prior growth factors
* At least 2 months since prior stem cell transplantation

  * No evidence of active graft-vs-host disease
* At least 8 weeks since prior monoclonal antibody therapy
* At least 7 days since prior antineoplastic biologic agents
* No prior bevacizumab
* No concurrent prophylactic growth factors
* No other concurrent immunotherapy or biologic therapy
* More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas) and recovered
* No concurrent chemotherapy
* Recovered from prior radiotherapy
* At least 4 months since prior craniospinal radiotherapy
* At least 4 months since prior radiotherapy to ≥ 50% of the pelvis
* At least 6 weeks since other prior substantial bone marrow radiotherapy
* At least 2 weeks since prior local palliative small-port radiotherapy
* No concurrent radiotherapy
* More than 28 days since prior major surgery
* At least 7 days since prior minor surgery (for limited purposes of tissue retrieval) and recovered
* At least 24 hours since prior placement of an indwelling IV catheter
* At least 1 week since prior full-dose anticoagulation therapy, including systemic thrombolytic agents, heparin, low-molecular weight heparin, and warfarin

  * Local intralumenal anticoagulants (e.g., heparin or tissue plasminogen activator) allowed to maintain patency of preexisting, permanent, indwelling IV catheters or peripheral IV catheters for blood sampling
* More than 1 week since prior antipyretic and anti-inflammatory medications (except acetaminophen)
* No concurrent full-dose anticoagulation therapy
* No concurrent anti-inflammatory medication
* Concurrent acetaminophen allowed
* No other concurrent cancer therapy
* No other concurrent investigational agents